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Abstract
Introduction: Transplantation of neural stem cells (NSCs) is increasingly suggested to become part of future
therapeutic approaches to improve functional outcome of various central nervous system disorders. However,
recently it has become clear that only a small fraction of grafted NSCs display long-term survival in the (injured)
adult mouse brain. Given the clinical invasiveness of NSC grafting into brain tissue, profound characterisation and
understanding of early post-transplantation events is imperative to claim safety and efficacy of cell-based
interventions.
Methods: Here, we applied in vivo bioluminescence imaging (BLI) and post-mortem quantitative histological
analysis to determine the localisation and survival of grafted NSCs at early time points post-transplantation.
Results: An initial dramatic cell loss (up to 80% of grafted cells) due to apoptosis could be observed within the
first 24 hours post-implantation, coinciding with a highly hypoxic NSC graft environment. Subsequently, strong
spatiotemporal microglial and astroglial cell responses were initiated, which stabilised by day 5 post-implantation
and remained present during the whole observation period. Moreover, the increase in astrocyte density was
associated with a high degree of astroglial scarring within and surrounding the graft site. During the two-week
follow up in this study, the NSC graft site underwent extensive remodelling with NSC graft survival further
declining to around 1% of the initial number of grafted cells.
Conclusions: The present study quantitatively describes the early post-transplantation events following NSC
grafting in the adult mouse brain and warrants that such intervention is directly associated with a high degree of
cell loss, subsequently followed by strong glial cell responses.
Introduction
Neural stem cells (NSCs) are defined as a population of
self-renewing multipotent progenitor cells present in the
developing and adult central nervous system (CNS) [1].
Despite their specific spatiotemporal occurrence in vivo,
ex vivo culture expansion of NSCs derived from various
sources (for example, embryonic or postnatal brain and
embryonic stem cells) was shown to be relatively
straightforward. Moreover, given the observation that ex
vivo cultured neurosphere-derived NSCs and mono-
layer-cultured NSC populations can be triggered to dif-
ferentiate into neurons, astrocytes and oligodendrocytes,
it is hoped that NSCs, or more committed (progenitor)
cells derived thereof, will become part of novel treat-
ment options for a variety of CNS disorders. To date,
several studies have reported the clinical benefit of
NSCs following intraperitoneal, intravenous, intraventri-
cular, intrathecal and intra-tissue grafting in various
models of neuroinflammation, neurodegeneration or
injury [1-4]. However, despite many suggestive literature
reports, it still remains elusive whether the actual clini-
cal benefit of grafted NSCs is due to cell integration,
trophic support, immunomodulation or other yet to be
defined mechanisms [5-7]. In this context, preceding
work by others [8] and us [9] determined the actual sur-
vival of grafted NSCs after at least two weeks to be less
then 2% upon direct grafting into healthy or inflamed
brain tissue. In addition, our preceding histological ana-
lyses indicated the presence of both microglia and
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astrocytes within and surrounding the NSC graft site at
two weeks post-implantation [9]. Following these obser-
vations, our next research aim was to determine
whether the observed glial cell responses: (i) were
directly executed against the grafted NSC (or their
reporter proteins), or (ii) resulted as a consequence of
immediate cell graft mortality. In order to investigate
both hypotheses, the present study determined the fol-
lowing parameters at multiple early time points (that is,
day 0, 1, 3, 5, 7 and 14) post-implantation: (i) the actual
survival of grafted NSC, (ii) the occurrence of cellular
hypoxia, and (iii) the occurrence and/or maintenance of
cell graft-induced glial cell responses.
Materials and methods
Cell implantation experiments
NSC genetically engineered with the Luciferase and
eGFP reporter proteins (NSC-Luc/eGFP, FVB-back-
ground) were cultured and characterised as previously
described [10]. For cell implantation experiments, adult
female Friend leukemia virus B (FVB)/NCrl mice (n =
33) were obtained from Charles River Laboratories (Wil-
mington, MA, USA - strain code 207). Cell implantation
of NSC-Luc/eGFP (2.5 × 105 cells in 2 μl PBS) was
reproducibly targeted to the right hemisphere at the fol-
lowing coordinates relative to bregma: 2 mm posterior,
2 mm lateral, and 2.25 mm ventral. All surgical inter-
ventions were performed under sterile conditions, as
previously described [9-11]. For all experiments, mice
were kept in a normal day-night cycle (12/12) with free
access to food and water. All experimental procedures
were approved by the Ethics Committee for Animal
Experiments of the University of Antwerp (UA)
(approval no. 2011/13).
In vivo bioluminescence imaging
In vivo bioluminescence imaging (BLI) was performed at
different time points post-implantation (day 1, 3, 5, 7,
10 and 14) using a real-time photon-imager system (Bio-
space, Centennial, CO, USA), according to previously
optimised procedures [10-12]. Using the M3 Vision soft-
ware (Biospace, Centennial, CO, USA), light emission
was measured from a fixed region of interest on the
mouse head, and values of signal intensity are presented
as the average number of photons/s/sr/cm2 over a 3-
minute time period. An additional region of interest was
drawn on the mouse shoulder and considered as back-
ground signal.
Histological analysis - immunofluorescence staining
Before sacrifice (1.5 hours), mice used in this study were
injected intraperitoneally with Hypoxyprobe-1 (HPI Inc,
Burlington, MA, USA), according to the manufacturer’s
instructions. Preparation of brain tissue for histological
examination was performed according to previously
optimised procedures [9]. Serial 10-μm thick cryosec-
tions were obtained from the entire implant region
using a Microm HM5000 cryostat (Prosan, Merelbeke,
Belgium), consecutively marked and missing slides were
noted. For further immunofluorescence analysis of tissue
sections, antibody staining was performed as previously
described [9,10,12], using the following antibodies: (i) a
rabbit anti-mouse ionized calcium binding adaptor
molecule 1 (Iba1) antibody (1/200) (Wako chemicals,
Osaka, Japan; 019-19714) and (ii) a rabbit anti-pimoni-
dazole (Hypoxyprobe-1) antibody (1/200) (HPI Inc., Bur-
lington, MA, USA; Pab2627), all in combination with a
secondary donkey anti-rabbit AlexaFluor 555 antibody
(1/500) (Life Technologies, Carlsbad, CA, USA;
A31572), (iv) a rabbit anti-mouse S100B antibody (1/
200) (Abcam, Cambridge, UK; 52642) in combination
with a secondary donkey anti-rabbit AlexaFluor 555
antibody (1/1000) (Life Technologies, Carlsbad, CA,
USA; A31572), (v) a mouse anti-mouse GFAP antibody
(1/400) (Millipore, Billerica, MA, USA; MAB360) in
combination with a secondary goat anti-mouse Alexa-
Fluor 555 (1/1000) (Life Technologies, Carlsbad, CA,
USA; A21127), and (vi) a chicken anti-mouse MBP anti-
body (1/200) (Millipore, Billerica, MA, USA; AB9348) in
combination with a secondary donkey anti-chicken
DyLight 549 (Jackson Immunoresearch, Suffolk, UK;
703-506-155). The presence of terminal deoxynucleoti-
dyl transferase dUTP nick end labelling (TUNEL)+
apoptotic cells was investigated using the In Situ Cell
Death Detection Kit TMR Red (Roche, Penzberg, Ger-
many; 12156792910), according to manufacturer’s
instructions. Nuclear staining was performed using a
TOPRO3 deep red stain (1/200) (Life Technologies,
Carlsbad, CA, USA).
Histological analysis - quantitative analysis
Quantitative analysis of cell graft survival, glial cell
responses and cellular hypoxia were performed using
NIH ImageJ analysis software (ImageJ) and TissueQuest
immunofluorescence analysis software (TissueGnostics
GmbH, Vienna, Austria), allowing determination of the
following parameters: (i) total graft site volume in mm3,
(ii) density of eGFPpos NSC-luc/eGFP within the graft
site provided in number of cells/mm3 (six data counts
per cell graft analysed), (iii) cell graft survival provided
in absolute numbers and as % calculated to the initial
number of grafted cells, (iv) density of Iba1pos microglia
within the graft site provided in number of cells/mm3
(three data counts per cell graft analysed), (v) density of
Iba1pos microglia within the implant border (that is,
region extending 100 μm from the implant site) pro-
vided in number of cells/mm3 (three data counts per
cell graft analysed), (vi) density of S100Bpos astrocytes
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within the graft site in number of cells/mm3 (three data
counts per cell graft analysed), (vii) density of S100Bpos
astrocytes within the implant border provided in num-
ber of cells/mm3 (three data counts per cell graft ana-
lysed), (viii) the degree of glial fibrillary acidic protein
(GFAP)pos astrogliosis within the graft site provided as
% astrogliosis (that is, image-covering of GFAP staining)
(one data count per cell graft analysed), (ix) the degree
of GFAPpos astrogliosis within the implant border pro-
vided as % astrogliosis (one data count per cell graft
analysed), (x) the percentage of Hypoxyprobe-1pos eGFP-
pos NSC versus total eGFPpos NSC within the implant
zone (one data count per cell graft analysed).
Statistical analysis
All statistical analyses were performed using the statisti-
cal package R, version 2.13.1, with linear mixed models
fitted using the lme function in the nlme package. Dif-
ferences in graft site volume between day 0 and day 14
post-grafting were tested using the Mann-Withney U-
test. The evolution over time of NSC graft survival was
modelled using piecewise linear regression, taking the
knot at day 1 post-implantation. Using this model, sepa-
rate regression slopes up to day 1 and beyond day 1
(that is, from on day 3) were estimated and tested for
significance. The evolution over time of the obtained in
vivo bioluminescence signal intensities, microglia densi-
ties, astrocyte densities and the degree of astrogliosis
was modelled using piecewise linear mixed model analy-
sis. A random intercept for individual was added to the
model to account for the dependence between observa-
tions from the same individual. Values for biolumines-
cence signal intensity, microglia densities and astrocyte
densities were log-transformed to obtain a more nor-
mally distributed outcome variable. The position of the
knot was determined based upon visual inspection of
the data. Separate regression slopes before and after the
knot were estimated and tested for significance. For all
analyses, a P-value < 0.05 was considered statistically
significant.
Results
Longitudinal in vivo bioluminescence imaging of neural
stem cell grafts
For cell grafting experiments, we used a previously engi-
neered NSC line expressing both the Luciferase and
eGFP reporter proteins (Figure 1A), further named as
NSC-Luc/eGFP [10]. Following grafting of 1.5 × 105
NSC-Luc/eGFP in the CNS of immune-competent FVB
mice (n = 33), longitudinal in vivo BLI was performed at
day 1 (n = 25), day 3 (n = 15), day 5 (n = 15), day 7 (n
= 10), day 10 (n = 5) and day 14 (n = 5) post-implanta-
tion. For quantitative analysis of the observed BLI sig-
nals, the mean cell graft-specific BLI signals from fixed
regions on top of the mouse head (Figure 1B) and the
mean background BLI signals from fixed control regions
on the mouse shoulder (Figure 1B) were plotted versus
time post-implantation (Figure 1C). Regression analysis
of the data indicates a significant decrease in BLI signal
beyond day 3 post-implantation (P < 0.0001), indicative
of a progressive decrease of cell viability within NSC-
Luc/eGFP grafts.
Quantitative analysis of neural stem cell graft survival
Histological analyses of brain tissue from cell-grafted
mice were performed at day 0 (4 hours post-implanta-
tion, n = 5), day 1 (n = 5), day 3 (n = 4), day 5 (n = 4),
day 7 (n = 4) and day 14 (n = 4) post-implantation. For
this, cryosections were prepared from the whole graft
site area and screened for the presence of eGFP-expres-
sing NSC-Luc/eGFP implants. Representative histologi-
cal images of NSC-Luc/eGFP implants, provided in
Figure 2 (first row), already indicate extensive cell death
at day 1 post-implantation. The latter is clearly visua-
lised by the loss of eGFP expression within NSC-Luc/
eGFP grafts at day 1 as compared to the uniform eGFP
expression within NSC-Luc/eGFP grafts at day 0. From
day 7 post-implantation, the necrotic core of NSC-Luc/
eGFP implants has disappeared, while remaining NSC-
Luc/eGFP have dispersed along the white matter tracts
of the capsula externa and corpus callosum. Larger
images of those presented in Figure 2 are provided in
Figure S1 in Additional file 1. Further quantitative ana-
lysis estimated the actual number of grafted NSC-Luc/
eGFP at day 0 post-implantation and the number of sur-
viving NSC-Luc/eGFP at day 1, day 3, day 5, day 7 and
day 14 post-implantation (Figure 3a). Presented data
indicate a dramatic initial cell loss (up to 80%) within
the first 24 hours post-implantation (P < 0.0001), which
slowly continues between day 1 and 14 post-implanta-
tion (P = 0.004). Based on the number of grafted cells at
day 0, graft survival was estimated to be 22%, 6%, 5%,
4% and 1% respectively, at day 1, day 3, day 5, day 7
and day 14 post-implantation (Figure 3a inset).
Excessive apoptotic cell loss coincides with cellular
hypoxia within NSC grafts
As shown by the representative images in Figure 2 (sec-
ond row), it is clear at day 0 and day 1 post-grafting
that the majority of grafted NSC-Luc/eGFP are under
hypoxic condition as demonstrated by immunostaining
of tissue sections for Hypoxyprobe-1 (an in vivo probe
for labelling of hypoxic cells). Further quantitative image
analysis indeed confirmed a high percentage of hypoxic
cells among (still) viable eGFP expressing NSC-Luc/
eGFP at day 0 (mean 74.3% ± standard deviation (SD)
8.3%) and day 1 (54.9% ± 5.5%) post-grafting, which was
not detected at later time points post-grafting in the few
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surviving NSC-Luc/eGFP. Moreover, as shown in Figure
4, already at 4 hours post-grafting (day 0) TUNEL reac-
tivity can be observed within the population of grafted
NSC-Luc/eGFP. In contrast, at day 1 post-grafting,
TUNEL reactivity is highly apparent within the eGFP-
negative necrotic core of the NSC-Luc/eGFP graft, but
not in the few surviving NSC-Luc/eGFP at the border of
the graft. Larger images of those presented in Figure 4
are provided in Figure S2 in Additional file 1. Based on
these data, we suggest that excessive cell loss observed
within the first 24 hours post-grafting might be (par-
tially) initiated by cellular hypoxia (and presumably also
lack of nutrients) within the core of NSC-Luc/eGFP
grafts, resulting in massive apoptotic cell death.
Figure 1 Longitudinal in vivo bioluminescence imaging of neural stem cell-Luciferase/enhanced green fluorescent protein (NSC-Luc/
eGFP) grafts. (A) In vitro characterisation of NSC-Luc/eGFP. Left, representative fluorescence microscopy image of Luciferase/eGFP-expressing
NSC (NSC-Luc/eGFP) used in this study. Green colour, direct eGFP fluorescence. Middle histogram overlay, representative flowcytometric analysis
of parental NSC and NSC-Luc/eGFP. Open black histogram, control background fluorescence in FL-1 green channel from parental NSC. Filled
green histogram, direct eGFP fluorescence in FL-1 green channel from NSC-Luc/eGFP. Right, in vitro bioluminescence analysis of 1 × 105 parental
NSC and NSC-Luc/eGFP. Data are expressed as photons/s/sr/cm2 from a 5-minute time period (± standard error of the mean (SEM), n = 4). (B) In
vivo bioluminescence imaging (BLI) - image aquisition. Representative time course image showing in vivo BLI of mice grafted with 1.5 × 105
NSC-Luc/eGFP in the central nervous system (CNS). Images were acquired at day 1 (n = 25), day 3 (n = 15), day 5 (n = 15), day 7 (n = 10), day
10 (n = 5) and day 14 (n = 5) post-implantation. Regions of interest are drawn on the mouse head, where NSC-Luc/eGFP were injected, and on
the mouse shoulder, considered as background signal. A representative time course image was chosen out of five mice imaged for the whole
time course. (C) In vivo BLI- image analysis. Quantitative analysis of in vivo BLI analysis at day 1, 3, 5, 7, 10 and 14 post-implantation. BLI signals
(in photons/s/sr/cm2) are provided as the mean (± SEM) for all mice analysed, both from the specific region of interest on the mouse head (red
bars) and from the control region of interest on the mouse shoulder (blue bars). Significant differences are described in the results section.
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Quantitative analysis of glial cell responses following
neural stem cell grafting
Since around 95% of cell graft mortality can be observed
within the first 48 hours following NSC-Luc/eGFP graft-
ing, glial cell responses are inevitable evoked. Therefore,
we investigated the temporal behaviour of microglia and
astrocytes following NSC-Luc/eGFP grafting. From the
representative data provided in Figure 2 (third row) no
direct microglial response can be observed at day 0
post-implantation, as indicated by the absence of
Figure 2 Histological analysis of neural stem cell (NSC) graft survival and endogenous glial cell responses. First row, NSC-Luciferase/
enhanced fluorescent green protein (Luc/eGFP) graft survival. Direct eGFP fluorescence (green) combined with TOPRO3 staining (false colour
representation in blue) at day 0, 1, 3, 5, 7 and 14 post-implantation. Representative images were chosen from multiple stained slides (n = 6 to 9
for eGFP/TOPRO3 combination) per mouse analysed at each time point. The provided scale bars indicate 200 μm. Second row, cellular hypoxia.
Direct eGFP fluorescence (green) combined with Hypoxyprobe-1staining (red) at day 0, 1, 3, 5, 7 and 14 post-implantation. Representative
images were chosen from two to five mice analysed at each time point. The provided scale bars indicate 50 μm. Third, fourth and fifth row,
endogenous glial cell behaviour. Direct eGFP fluorescence (green) combined with TOPRO3 staining (false colour representation in blue) and
combined with immunofluorescence staining for ionized calcium binding adaptor molecule 1 (Iba1) (red, fourth row), S100 calcium binding
protein B (S100B) (red, fifth row) or glial fibrillary acidic protein (GFAP) (red, sixth row) at day 0, 1, 3, 5, 7 and 14 post-implantation.
Representative images were chosen from multiple stained slides (n = 3 for eGFP/TOPRO3/Iba1 combination, n = 3 for eGFP/TOPRO3/S100B
combination and n = 1 for eGFP/TOPRO3/GFAP) per mouse analysed at each time point (n = 4/5). The provided scale bars indicate 50 μm for
Iba1 and S100B images and 200 μm for GFAP images. Sixth row, graft site remodelling. Direct eGFP fluorescence (green) combined with myelin
base protein (MBP) staining (red) at day 0, 1, 3, 5, 7 and 14 post-implantation. Representative images were chosen from multiple mice analysed
at each time point (n = 2). The provided scale bars indicate 200 μm.
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staining for Iba1pos microglia. However, on day 1 post-
implantation, and coinciding with the presence of a
large number of necrotic cells, an accumulation of Iba1-
pos microglia within and surrounding the graft site can
be observed, which remains detectable from day 3 post-
implantation. Next, although the number of S100Bpos
astrocytes does not appear to change largely over time
(Figure 2, fourth row), a high degree of astrogliosis,
based on staining for GFAP (Figure 2, fifth row), is
apparent at from day 3 post-implantation. Further quan-
titative image analysis of glial cell responses evoked by
grafted NSC/Luc-eGFP focused on: (a) the implant site,
delineated based on eGFP expression, and (b) the
implant border, delineated as a 100-μm border around
the implant site. Regarding microglial cell recruitment
(Figure 3b and 3c), Iba1pos microglia density significantly
increases until day 3 post-implantation within and sur-
rounding the graft site (for both P < 0.0001). However,
no further increase (or decrease) in microglia density
was observed within or surrounding the graft site
beyond day 3 post-implantation (respectively P = 0.76
and P = 0.96). Regarding astroglial cell recruitment
Figure 3 In vivo cell graft and glial cell behaviour - quantitative analysis. (a) Survival of grafted neural stem cell-Luciferase/enhanced
fluorescent green protein (NSC-Luc/eGFP). Presented data are the estimated total number of eGFP-expressing NSC-Luc/eGFP detected within the
implant site for each mouse analysed (n = 5 for day 0, n = 5 for day 1, n = 4 for day 3, n = 4 for day 5, n = 4 for day 7 and n = 4 for day 14).
The red line indicates the average total number of eGFP-expressing NSC-Luc/eGFP at each time point analysed. The inset graph represents the
mean % (± standard error of the mean (SEM)) of NSC-Luc/eGFP graft survival at each time point analysed from day 1 post-implantation.
Significant differences are described in the results section. (b-e) Cellular density of ionized calcium binding adaptor molecule 1 (Iba1)pos microglia
and S100 calcium binding protein B (S100B)pos astrocytes within the implant site and within the implant border. Presented data are the ln(x)-
transformed values of estimated total density of microglia and astrocytes within the implant border for each mouse analysed (n = 4 for day 0, n
= 5 for day 1, n = 4 for day 3, n = 5 for day 5, n = 4 for day 7 and n = 4 for day 14). The red line indicates the average total cellular density at
each time point analysed. Significant differences are described in the results section. (f) Astrogliosis within the implant site and implant border
(both areas are combined here). Presented data indicate the average degree of glial fibrillary acidic protein (GFAP)pos astrogliosis (based on
image coverage after GFAP staining) for each mouse analyses (n = 4 for day 0, n = 5 for day 1, n = 4 for day 3, n = 5 for day 5, n = 4 for day 7
and n = 4 for day 14). The red line indicates the average degree of astrogliosis at each time point analysed. Significant differences are described
in the results section.
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(Figure 3d and 3e), S100Bpos astrocyte density signifi-
cantly increased within the graft site until day 5 post-
grafting (P < 0.0001), with no increase beyond day 5 (P
= 0.27). Within the implant border, astrocyte density
slightly increased between day 0 and day 14 post-graft-
ing (P = 0.0021). All absolute microglia and astrocyte
cell densities within and surrounding the graft site at
day 0, 1, 3, 5, 7 and 14 are provided in Table 1.
Although the number of astrocytes recruited within and
surrounding the graft site is less impressive compared to
microglia recruitment, staining for GFAP was performed
in order to determine GFAPpos astroglial scarring within
and surrounding the graft site. Presented data (Figure
3f) clearly indicate that the degree of GFAPpos astroglio-
sis within and surrounding the graft site (both areas
combined) significantly increases throughout the whole
observation period, with the highest increase occurring
prior to day 3 post-implantation (P < 0.0001), and a
reduced, although significant (P = 0.006), increase
beyond day 3 post-implantation.
Disruption of CNS architecture following neural stem cell
transplantation
Inevitably, cell grafting in the CNS will induce damage
to the CNS architecture due to needle insertion and the
subsequent injection of a cell suspension. As shown by
the representative images in Figure 2 (sixth row), it is
clear that both the CNS architecture, as visualised by
staining for myelin basic protein (MBP), and the NSC-
Luc/eGFP graft site, as visualised by the presence of
eGFP-expressing cells, undergo significant changes at
early stages post-grafting. While initially grafted NSC-
Luc/eGFP are clustered together and myelin conforma-
tion of the capsula externa is temporally spread out, this
gradually remodels as the limited number of surviving
NSC-Luc/eGFP spread along the capsula externa/corpus
callosum, and the disturbance in myelin conformation
partially restores itself. The latter is accompanied with a
reduction of graft site volume (that is, the area in which
eGFP-expressing cells can be found) from 0.35 ± (SD)
0.09 mm3 at day 0 post-grafting to 0.07 ± 0.07 mm3 at
day 14 post-grafting (P = 0.015).
Discussion
Over the past years, neural stem cell transplantation has
been recognized as a promising novel therapeutic tool
to treat CNS disorders for which today, no effective
therapies are available. However, successful functional
integration of grafted NSCs (or in vitro/in vivo NSC-
derived cell types) is one of the major challenges in
Figure 4 Histological analysis of in vivo neural stem cell (NSC) graft apoptosis. Direct enhanced fluorescent green protein (eGFP)
fluorescence (green) combined with TOPRO3 staining (false colour representation in blue) and combined with the control immunofluorescence
staining for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) (red, CONTROL STAINING) and the specific
immunofluorescence staining for TUNEL+ apoptotic cells (red, TUNEL STAINING) at day 0 and 1 post-implantation. Representative images were
chosen from multiple mice analysed at each time point (n = 2). The provided scale bars indicate 100 μm.
Table 1 Astroglial and microglial densities following intracerebral implantation of NSC-Luc/eGFP.
Time post-implantation
Day 0 Day 1 Day 3 Day 5 Day 7 Day 14
Implant site
Microglia density 1,293 ± 768 10,017 ± 10,678 104,712 ± 75555 146,551 ± 188,791 94,803 ± 126,268 24,017 ± 250,036
Astrocyte density 5,382 ± 5,483 7,376 ± 5,653 18,059 ± 12,436 25,515 ± 5,986 28,900 ± 9,807 32,647 ± 15,108
Border zone
Microglia density 1,537 ± 1,071 5,367 ± 5,951 24,551 ± 17,042 34,467 ± 33,349 25,062 ± 22,264 41,693 ± 44,628
Astroglial density 22,010 ± 6,202 17,757 ± 3,149 22,798 ± 4,216 25,308 ± 4,943 27,262 ± 5,647 34,603 ± 11,392
Absolute microglia and astrocyte cell densities (in number of cells/mm3 ± SD) within the implant site and the implant border at day 0, day 1, day 3, day 5, day 7
and day 14 post-grafting.
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current neuroscience research, and if successful, will
have an enormous impact on the future development of
cell replacement therapies for CNS disorders. In order
to contribute to this understanding, we have investigated
the spatiotemporal evolution of NSC graft behaviour
and endogenous glial cell responses at early time points
post-implantation.
With regard to direct grafting of NSCs in CNS tissue,
our results demonstrate that this procedure immediately
results in: (i) significant disruption of the CNS architec-
ture (Figure 2, sixth row) and (ii) substantial cell graft
mortality (Figure 3a). First, the observed disruption of
CNS architecture (although partially restored over time)
will remain inevitable as long as cells (or cell-seeded
scaffolds) are directly implanted into CNS tissue.
Although alternative administration routes (that is,
intraventricular, intrathecal or intravenous) have been
suggested to facilitate cell delivery into injured CNS tis-
sue, the cell number arriving at the target site is gener-
ally nihil to a few representative cells detected by
histological analysis [13-15]. Second, apoptotic cell
death within the first 24 hours post-grafting (Figure 4)
can most likely be explained by the lack of oxygen (Fig-
ure 2, second row) and/or nutrients delivered to the
NSC graft, which, in fact, is introduced without any
structural and/or functional support. More recently,
novel biomimetic strategies are emerging aiming to cre-
ate a permissive micro environmental niche, thereby
enhancing survival, differentiation and integration of
grafted NSCs [16-18]. The latter will be inevitable, as a
substantial amount of grafted cells need to survive fol-
lowing transplantation in order to functionally partici-
pate in neuronal circuitries. Of note, while we used both
in vivo BLI (Figure 1c) and post-mortem histological
analysis (Figure 3a) to determine cell graft survival, it
should be noted that the observed in vivo BLI signals at
day 1 and day 3 post-grafting are resulting from respec-
tively 20% and 5% of the original number of grafted
cells. Although we and others have associated this early
in vivo BLI signal with complete cell graft survival, our
results now clearly indicate that precaution has to be
taken in the interpretation of early in vivo BLI data
[10,11]. Nevertheless, in vivo BLI remains an interesting
tool for longitudinal assessment of cell graft survival, as
progressive cell loss of implanted NSC could clearly be
demonstrated from on day 3 post-implantation (Figure 1c).
With regard to the observed glial cell responses, these
are not surprising as the majority (up to 95%) of grafted
NSCs already die within the first 24 to 48 hours post-
grafting (Figure 3a). However, in our preceding studies
regarding autologous and allogeneic stem cell grafting in
the CNS of immune competent mice, we suggested that
the occurrence of glial cell responses was most likely
due to the recognition of the cellular implant itself,
whereby autologous reporter-gene modified cellular
grafts were immune-tolerated and allogeneic cellular
grafts were immune-rejected. However, our early studies
did not include full quantitative analysis of in vivo BLI
and histology data. Based on our new data showing that
NSC grafts already display a high degree of mortality
before the initiation of glial cell responses (Figure 3b-f),
the observed glial cell responses are more likely to be
associated with phagocytocis of cellular debris rather
than active recognition of grafted autologous NSC.
Nevertheless, based on our preceding data regarding full
rejection of allogeneic (but not autologous) cellular
grafts, active distinguishment of autologous and allo-
geneic cellular grafts by microglia (or astrocytes) will
thus most likely be occurring during or after the initial
clearance of cellular debris. Following initial activation
of glial cell responses, survival of grafted autologous
NSC further declines to around 1% by week 2 post-
implantation. Moreover, although endogenous microglia
and astrocytes are able to produce either pro-inflamma-
tory/neurotoxic or anti-inflammatory/neuroprotective
factors depending on the type of activation [19,20], it is
highly likely that the evoked immune responses follow-
ing NSC implantation create an inhibitory pro-inflam-
matory environment, thereby further limiting the long-
term survival of transplanted NSC [21]. Of note, addi-
tional immunophenotypical stainings were performed to
determine the in vivo differentiation potential of the few
surviving NSC-Luc/eGFP (data not shown). Results indi-
cated that grafted NSC-Luc/eGFP did not change phe-
notypic properties between day 0 and day 14 post-
grafting, that is, They remained SOX2pos (as NSC mar-
ker), S100Bneg (as astrocyte marker), NeuNneg (as neuro-
nal marker) and CC1neg (as oligodendrocytes marker).
Likewise, proper in vivo differentiation and functional
integration of the few surviving NSC is most likely
inhibited by an endogenous glial-cell-induced pro-
inflammatory immune environment [22-24].
Conclusions
The present study quantitatively describes the early
post-transplantation events following NSC grafting in
the adult mouse brain and warrants that such interven-
tion is associated with an immediate high degree of cell
loss. The latter is subsequently followed by strong glial
cell responses, presumably creating a non-permissive
environment, which limit proper migration, differentia-
tion and integration of grafted NSC into the host tissue.
Unfortunately, these observations are generally not con-
sidered when evaluating the potential of pre-clinical cell
therapy studies, as most reports lack detailed cell graft
survival and/or glial reactivity analysis at early and late
time-points post-grafting. Moreover, it is important to
note that early NSC graft mortality and subsequent glial
Reekmans et al. Stem Cell Research & Therapy 2012, 3:56
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cell responses themselves might be responsible for many
of the observed beneficial effects following cell trans-
plantation in CNS disorders [2]. We therefore under-
score the current need for a profound characterisation
of all cellular and/or molecular interactions following
cell grafting in the CNS, as the full potential of NSC
transplantation therapy can only be determined follow-
ing better understanding (and manipulation) of NSC
graft survival and inhibitory immune responses.
Additional material
Additional file 1: Histological analysis of neural stem cell (NSC)
graft survival, endogenous glial cell responses and in vivo NSC
graft apoptosis. This file contains larger images of those presented in
Figure 2 (Figure S1) and Figure 4 (Figure S2).
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